Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
4.390
-0.130 (-2.88%)
At close: Apr 28, 2026, 4:00 PM EDT
4.280
-0.110 (-2.51%)
Pre-market: Apr 29, 2026, 8:54 AM EDT
Prelude Therapeutics Revenue
In the year 2025, Prelude Therapeutics had annual revenue of $12.14M with 73.43% growth. Prelude Therapeutics had revenue of $5.64M in the quarter ending December 31, 2025, with 41.00% growth.
Revenue (ttm)
$12.14M
Revenue Growth
+73.43%
P/S Ratio
36.36
Revenue / Employee
$153,671
Employees
79
Market Cap
441.43M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 205.07M |
| REGENXBIO | 170.44M |
| Ginkgo Bioworks Holdings | 170.16M |
| 4D Molecular Therapeutics | 85.21M |
| XOMA Royalty | 52.15M |
| Entrada Therapeutics | 25.42M |
| Armata Pharmaceuticals | 4.90M |
PRLD News
- 9 days ago - Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering - GlobeNewsWire
- 9 days ago - Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026 - GlobeNewsWire
- 14 days ago - Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer - GlobeNewsWire
- 6 weeks ago - Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting - GlobeNewsWire
- 7 weeks ago - Prelude Therapeutics Transcript: Conference - Transcripts
- 7 weeks ago - Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026 - GlobeNewsWire
- 3 months ago - Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor - GlobeNewsWire
- 5 months ago - Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs - GlobeNewsWire